Non Ischemic Cardiomyopathy clinical trials

Explore recruiting non ischemic cardiomyopathy clinical trials.

Recruiting non ischemic cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Ischemic Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

(ASK-CHF2-CS201) A Phase 2, adaptive, double-blinded, placebo-controlled, randomized, multi-center trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of AB-1002 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy

Austria, Spain, Germany, Netherlands, Hungary, Belgium +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Ischemic Cardiomyopathy trials by city

Non Ischemic Cardiomyopathy in Toronto Non Ischemic Cardiomyopathy in Vancouver Non Ischemic Cardiomyopathy in Montreal Non Ischemic Cardiomyopathy in Calgary Non Ischemic Cardiomyopathy in Edmonton Non Ischemic Cardiomyopathy in Ottawa Non Ischemic Cardiomyopathy in Winnipeg Non Ischemic Cardiomyopathy in Quebec City Non Ischemic Cardiomyopathy in Hamilton Non Ischemic Cardiomyopathy in Kitchener Non Ischemic Cardiomyopathy in London Non Ischemic Cardiomyopathy in Halifax Non Ischemic Cardiomyopathy in New York Non Ischemic Cardiomyopathy in Los Angeles Non Ischemic Cardiomyopathy in Chicago Non Ischemic Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease